Vasomune Therapeutics Inc
Vasomune Therapeutics Inc. is a private biotechnology company based in Toronto, Ontario, that specializes in the development of AV-001, a first-in-class fully synthetic PEGylated peptide designed to target the Tie2 receptor. The company's innovative approach focuses on enhancing vascular stability, barrier integrity, and endothelial quiescence through the activation of this critical receptor.
With a commitment to advancing therapeutic solutions, Vasomune Therapeutics is at the forefront of biotechnology, leveraging its expertise to address significant medical challenges. The company's research and development efforts are centered on creating impactful treatments that improve patient outcomes.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2023. All rights reserved.